Literature DB >> 3621134

The measurement of performance in childhood cancer patients.

S B Lansky, M A List, L L Lansky, C Ritter-Sterr, D R Miller.   

Abstract

The performance status of the child with cancer is an important outcome consideration in pediatric oncology research and practice. However, no single measure for children has been available. This is a report of the development and standardization of such a scale. The play-performance scale for children is a parent-rated instrument which records usual play activity as the index of performance. Performance status ratings were obtained on three groups of children: patients (n = 98), patients' siblings (n = 29), and an independent sample of hospital employees' children (n = 40). Children with all types and stages of childhood malignant neoplasms were represented. Test results established the parent as a competent, reliable rater and demonstrated the validity of the scale. Interrater reliability was examined using correlational statistics and percentage agreement. Agreement between parents was good, and there were no systematic rater biases. In addition, parents' ratings significantly discriminated differences in levels of functioning (mean score, patients 75.4 versus siblings 97.4). Correlational and analysis of variance (ANOVA) procedures demonstrated that the play-performance scale was significantly related to the global performance measures of experienced clinicians and was sensitive to change. Inpatients received a mean score of 42.3, outpatients 90.7, and normals 98.2. These findings indicate that the scale is both feasible and effective. It is concise, can be administered repeatedly even to extremely ill patients, and uses parents as observer reporters. The play-performance scale for children provides quantifiable, reproducible, and meaningful data, which is necessary for effective monitoring and management of the child with cancer.

Entities:  

Mesh:

Year:  1987        PMID: 3621134     DOI: 10.1002/1097-0142(19871001)60:7<1651::aid-cncr2820600738>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  74 in total

1.  Validity, specificity, feasibility and acceptability of a brief pediatric distress thermometer in outpatient clinics.

Authors:  Lori Wiener; Haven Battles; Sima Zadeh; Brigitte C Widemann; Maryland Pao
Journal:  Psychooncology       Date:  2015-11-30       Impact factor: 3.894

2.  Functional status at listing predicts waitlist and posttransplant mortality in pediatric liver transplant candidates.

Authors:  Emily R Perito; John Bucuvalas; Jennifer C Lai
Journal:  Am J Transplant       Date:  2018-12-31       Impact factor: 8.086

3.  Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.

Authors:  Katherine A Rauen; Anuradha Banerjee; W Robert Bishop; Jennifer O Lauchle; Frank McCormick; Martin McMahon; Teri Melese; Pamela N Munster; Sorena Nadaf; Roger J Packer; Judith Sebolt-Leopold; David H Viskochil
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

Review 4.  Good clinical practice and the conduct of clinical studies in pediatric oncology.

Authors:  Susan Devine; Ramzi N Dagher; Karen D Weiss; Victor M Santana
Journal:  Pediatr Clin North Am       Date:  2008-02       Impact factor: 3.278

5.  High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

Authors:  Antonio Pérez-Martínez; Alvaro Lassaletta; Marta González-Vicent; Julián Sevilla; Miguel Angel Díaz; Luis Madero
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

6.  Modern Outcomes of Mechanical Circulatory Support as a Bridge to Pediatric Heart Transplantation.

Authors:  Brody Wehman; Kristen A Stafford; Gregory J Bittle; Zachary N Kon; Charles F Evans; Keshava Rajagopal; Nicholas Pietris; Sunjay Kaushal; Bartley P Griffith
Journal:  Ann Thorac Surg       Date:  2016-02-22       Impact factor: 4.330

Review 7.  Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.

Authors:  E J Estlin; S Ablett; D R Newell; I J Lewis; L Lashford; A D Pearson
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).

Authors:  Lori Wiener; Haven Battles; Sima Zadeh Bedoya; Andrea Baldwin; Brigitte C Widemann; Maryland Pao
Journal:  J Genet Couns       Date:  2017-07-23       Impact factor: 2.537

9.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

10.  High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.

Authors:  Antonio Pérez-Martínez; Victor Quintero; Marta González Vicent; Julián Sevilla; Miguel Angel Díaz; Luis Madero
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.